The major mechanism for the repair of DNA doublestrand breaks (DSBs) in mammalian cells is non-homologous end-joining (NHEJ), a process that involves the DNA-dependent protein kinase [1,2], XRCC4 and DNA ligase IV [3-6]. Rodent cells and mice defective in these components are radiation-sensitive and defective in V(D)J-recombination, showing that NHEJ also functions to rejoin DSBs introduced during lymphocyte development [7, 8] . 180BR is a radiosensitive cell line defective in DSB repair, which was derived from a leukaemia patient who was highly sensitive to radiotherapy [9-11]. We have identified a mutation within a highly conserved motif encompassing the active site in DNA ligase IV from 180BR cells. The mutated protein is severely compromised in its ability to form a stable enzyme-adenylate complex, although residual activity can be detected at high ATP concentrations. Our results characterize the first patient with a defect in an NHEJ component and suggest that a significant defect in NHEJ that leads to pronounced radiosensitivity is compatible with normal human viability and does not cause any major immune dysfunction. The defect, however, may confer a predisposition to leukaemia.
Results and discussion
To investigate the possibility that 180BR cells might be defective in NHEJ, we examined the expression and functions of the known components of the pathway in both primary 180BR and SV40-transformed 180BR (180BRneo) cell lines. The three components of the DNA-dependent protein kinase (DNA-PK) -Ku70, Ku80 and DNA-PKcs -were expressed at normal levels, and functional assays showed normal levels of DNA endbinding and DNA-PK activities ( Figure 1 ) [11] . In contrast, the level of XRCC4 was slightly reduced compared with control primary and immortalised cells (1BR and 1BRneo, respectively) derived from a normal human fibroblast and, more markedly, the level of DNA ligase IV was variable and frequently substantially reduced. Following changes to the extraction procedure, however, 180BR cell extracts were obtained with close to normal levels of XRCC4 and DNA ligase IV ( Figure 2a , lanes 1,2), suggesting that XRCC4 or DNA ligase IV might be unusually sensitive to proteolysis in 180BR cells.
No differences in the sequences of the XRCC4 cDNA from 180BRneo and MRC5VI control cells were revealed by reverse-transcription PCR (RT-PCR). Examination of the sequence of the DNA ligase IV cDNA from 180BRneo and normal 1BRneo cells by RT-PCR revealed two polymorphisms or potential errors in the published sequence (See Supplementary material published with this article on the internet). More significantly, this analysis identified a G to A mutational change at position 833 of the DNA ligase IV cDNA in 180BRneo cells compared with 1BR cells, which results in an arginine-to-histidine substitution at amino acid position 278 (R278H; see Supplementary material). The same mutational change was present in the primary 180BR cell line. The mutation creates an NdeI restriction site, which was shown to be present in an RT-PCR product from 180BR but not 1BR cells (see Supplementary material). Finally, the presence Analysis of 180BR and 1BR cells for the expression of proteins involved in NHEJ. Whole cell extracts (10 µg of protein) of the indicated cell lines were loaded onto 6% polyacrylamide gels and analysed by western blotting using antibodies against DNA ligase IV, Ku80, Ku70 or XRCC4. of the mutation was confirmed by sequence analysis of the full-length DNA ligase IV gene from genomic DNA and by NdeI digestion of the relevant fragment (see Supplementary material). There was no evidence of a wild-type allele, suggesting that the patient is homozygous for this mutation, although the possibility of a single mutated allele accompanied by a deletion of the other allele has not been ruled out. This mutation is not a common polymorphism, and has not been observed in 200 human DNAs examined (F. Carlomagno, personal communication).
The R278H mutation lies within the motif KxDGxR (using the single-letter amino-acid code in which x is any amino acid), which is conserved between ATP-dependent DNA ligases and GTP-dependent mRNA-capping enzymes and includes the predicted active-site lysine (see Supplementary material) [12] [13] [14] . The lysine ε-amino group in this motif forms a covalent bond with AMP in the ligase-AMP complex, raising the possibility that 180BR might be impaired in enzyme-adenylate complex formation. Using extracts of 1BRneo and 180BRneo cells prepared under defined protein-inhibitor conditions, in which DNA ligase IV protein levels from 180BRneo cells were only marginally decreased (Figure 2a, lanes 1,2) , the level of DNA ligase IV in the material immunoprecipitated using anti-XRCC4 antibodies was similarly only marginally decreased (Figure 2a, lanes 3-6) . Whereas the material immunoprecipitated from 1BRneo cell extracts by the anti-XRCC4 antibody yielded an adenylated product with the size anticipated for the DNA ligase IV-AMP complex, no protein-adenylate complex was obtained from 180BRneo cell extracts (Figure 2a ). These results show that the defect in 180BRneo markedly decreases the ability of DNA ligase IV to form an enzyme-adenylate complex but that the ligase's ability to interact with XRCC4 is not impaired.
We next measured the ability of the immunoprecipitated protein complex from 1BRneo and 180BRneo cell extracts to ligate a nick in a double-stranded DNA oligonucleotide for 30 minutes at room temperature. Surprisingly, only around two-fold less ligase activity was detected in 180BRneo cell extracts compared with extracts from 1BRneo cells, even though no stable enzyme-adenylate intermediate was detected in the same 180BRneo cell extracts (Figure 2b ). The adenylation and ligation assays were carried out using markedly different ATP concentrations, however. Because analysis of the 180BR cell extracts was limited by the decreased stability of the mutant DNA ligase IV, we used protein expressed in vitro for further analysis. The R278H mutation was introduced into fulllength DNA ligase IV cDNA and protein-adenylate complex formation examined using wild-type and mutant proteins expressed in vitro. The analysis was conducted in either the absence or presence of XRCC4 (Figure 3a,b) . In both cases, no adenylation activity was detected using the mutant R278H DNA ligase IV. Adenylation reactions were carried out using ~0.2 µM ATP whereas the ligation reactions were carried out at 1 mM ATP. When higher ATP The R278H mutation impairs DNA ligase IV enzyme activities.
(a) Whole-cell extracts (WCEs; 50 µg protein) of 1BRneo and 180BRneo cells were analysed by western blotting using antibodies against DNA ligase IV (lanes 1,2). Only slightly reduced levels of DNA ligase IV were recovered from 180BRneo cells compared with the results shown in Figure 1 , where protease inhibitor cocktail tablets were not used during extraction. Because DNA ligase IV antibodies are not efficient in immunoprecipitation (IP), we used anti-XRCC4 antibodies, which efficiently coimmunoprecipitate DNA ligase IV [4] , to extract DNA ligase IV from WCEs (6 mg). DNA ligase IV exists endogenously as an enzyme-adenylate complex; we therefore examined DNA ligase IV-adenylate formation either with or without previous treatment with 5 mM inorganic pyrophosphate (+ or -PP i , respectively) for 15 min. PP i disrupts preformed AMP-ligase complexes [5, 21] . One tenth of each sample was examined by western blotting (lanes 3-6) and the remainder was used for an assay of adenylation. DNA ligase I was not detectable by western blotting.
(b) WCE (2.5 mg protein) of 1BRneo or 180BRneo cells was immunoprecipitated using anti-XRCC4 antibodies and the immunoprecipitated material treated with PP i as described above and then examined for ligase activity. In other experiments the PP i treatment was omitted and identical ligation was observed. The ligation products were separated by 12% denaturing PAGE. The sizes of the singlestranded oligonucleotides are as indicated. The 33mer was radiolabelled and ligation produced a radiolabelled 50mer product. The immunoprecipitated material gave an adenylation product from 1BRneo but not 180BRneo cell extracts similar to that shown in Figure 2a . The immunoprecipitated material from both cell lines had similar levels of DNA ligase IV, as assessed by western blotting (data not shown).
concentrations were used in the adenylation reaction, low but residual adenylation activity could be detected using the R278H mutant protein (Figure 3c ). Thus, the 180BR mutation severely inhibits, but does not abolish, the ability of DNA ligase IV to form an enzyme-adenylate intermediate. As found with the cell-free extracts, the mutation does not inhibit interaction with XRCC4.
It has not been possible so far to derive immortalised 180BR cells. The impact of the R278H mutation on DNA ligase IV activity in vivo was therefore investigated using S. cerevisiae as a model organism, because yeast ligase IV (Lig4p or Dnl4p) is known to function in NHEJ [15] [16] [17] .
No detectable stable DNA ligase IV-adenylate complex was observed in a yeast lig4 deletion strain expressing the corresponding R278H mutation (yeast R287H), in contrast to cells expressing wild-type Lig4p (Figure 4a ). The mutation had no impact on the interaction of Lig4p with the yeast XRCC4 homologue Lif1p (data not shown) [18] .
Using an in vivo plasmid-rejoining assay, NHEJ was shown to be impaired but not abrogated in cells expressing the R287H mutant protein (Figure 4b ). In contrast, mutation of Arg287 to alanine (R287A) or mutation of the active-site lysine residue Lys282 to alanine (K282A) dramatically reduced NHEJ (Figure 4b ). Although deletion of lig4 does not sensitise the yeast strains to radiation, rad52/lig4 double mutants show elevated radiosensitivity compared with rad52 single mutants [16, 17] . Expression of wild-type Lig4p complements the radiosensitivity defect of the lig4 disruption in the rad52 background, whereas expression of the R287H mutant protein does not fully complement the defect (Figure 4c ). These data show that Lig4p bearing the R287H mutation is impaired, but not completely defective, in its DSB-rejoining function and provide strong evidence that this mutation is responsible for the radiosensitivity of 180BR cells.
These findings confirm a role for DNA ligase IV in DSB repair in mammalian cells, and identify LIG4 as one of the few characterised genes, in addition to ATM, NBS1 and possibly BRCA1 and BRCA2, that contribute to human Brief Communication 701
Figure 3
Examination of mutant and wild-type DNA ligase IV expressed in vitro.
(a) Amino-terminally histidine (His)-tagged mutant (R278H) and wild-type (WT) DNA ligase IV was expressed in a rabbit reticulocyte lysate as described in Materials and methods. Expressed protein was immunoprecipitated using an anti-His antibody and immunoprecipitates were examined for DNA ligase IV expression by western blotting using an antibody against DNA ligase IV (upper panel) and by an adenylation assay (lower panel). (b) His-and S-tagged mutant and wild-type DNA ligase IV were coexpressed with His-tagged XRCC4 in bacteria. In the absence of coexpressed XRCC4 little soluble DNA ligase IV protein was synthesised. DNA ligase IV-XRCC4 complexes were recovered using S-protein agarose and analysed by Coomassie blue staining or used in an adenylation assay. Similar results were obtained when ligase IV and XRCC4 were purified by Ni-NTA agarose chromatography (data not shown). Western blot analysis confirmed the recovery of these proteins (data not shown). (c) The His-tag-purified, coexpressed ligase IV-XRCC4 complex was used in adenylation assays in the presence of either 0.2, 2 or 20 µM ATP. Samples were resolved by SDS-PAGE and, after transfer to nitrocellulose, filters were probed with an antibody against DNA ligase IV to confirm that equal levels of DNA ligase IV had been used in each assay. Adenylated proteins were detected by phosphorimager analysis of the same filter used in western blot analysis. radiosensitivity [6, 8] . Despite displaying pronounced radiation sensitivity, 180BR cells are not significantly defective in V(D)J recombination and the patient did not display overt immunodeficiency [9, 11] . The most likely explanation for this is that the residual DNA ligase IV activity in 180BR cells is sufficient for V(D)J recombination and for its reported essential role(s) [8, 19] but does not suffice for efficient repair of radiation-induced DSBs, for which abundant activity may be required. These findings have important implications for the impact of defects in NHEJ on human health, as they show that defects conferring significant radiosensitivity need not be associated with immune dysfunction. Finally, the patient from whom 180BR cells were derived developed acute lymphoblastic leukaemia at age 14 [9] . Pronounced radiosensitivity is rare among leukaemia patients and major defects in NHEJ components are unlikely to contribute significantly to the incidence of leukaemia. Nevertheless, it is possible that minor defects in NHEJ confer mild radiosensitivity and a predisposition to leukaemia, and that these could contribute significantly to the incidence of leukaemia in the general population. Our data also raise the possibility that variations in NHEJ might contribute to the variation between patients in their clinical radiosensitivity, a major obstacle in optimising radiotherapy.
Materials and methods

Immunoblotting, adenylation and ligation
Whole cell extracts were prepared by the method of Scholer et al. [20] . The anti-XRCC4 antibody, SJ4A, was raised against full-length XRCC4 protein [4] ; the anti-DNA ligase IV antibody was raised against carboxyterminal residues 550-844 of DNA ligase IV. DNA ligase IV from whole cell extracts was immunopurified using anti-XRCC4 antibodies. The immunoprecipitate was resuspended in adenylation buffer (see Supplementary materials) and adenylation was carried out with 10 µCi [α-32 P]ATP (800 Ci/mmol) at room temperature for 15 min, or with concentrations of ATP as stated [5] . For ligation, 1 mM ATP was added to the resuspended proteins together with the substrate, a radiolabelled 33mer plus an unlabelled 17mer annealed to a complementary 50mer to create a nicked double-stranded oligonucleotide [5] .
Expression of recombinant DNA ligase IV
For the in vitro transcription-translation system, amino-terminally Histagged DNA ligase IV cDNA was subcloned in-frame into the mammalian expression vector pcDNA3 (Invitrogen) and expressed using Promega TNT T7 Quick Coupled Transcription/Translation System. For the bacterial expression system, DNA ligase IV cDNA was cloned inframe downstream of the His-and S-tag of pET30 (Novagen). DNA ligase IV and XRCC4 were coexpressed in bacterial cells and purified using the His and S tags.
Yeast mutagenesis, strains and assays
The lig4 mutant strain, plasmid repair assays and survival analysis were carried out as described previously [16] .
Supplementary material
Additional methodological details are published with this paper on the internet. 
Identification of a defect in
Supplementary materials and methods
Cell culture
180BRneo is an SV40-transformed but not immortalised cell line derived from the 180BR primary human fibroblast line [S1] . 1BR3 is a normal primary fibroblast line; 1BRneo and MRC5VI are two SV40-immortalised human fibroblast lines, which were used as controls. Cells were cultured in Minimum Essential Medium (MEM) supplemented with 15% foetal calf serum (FCS), penicillin and streptomycin, as described previously [S2] .
Immunoblotting
In initial experiments, whole cell extracts were prepared by the method of Scholer et al. [S3] . In later experiments, which gave stable DNA ligase IV, the protease inhibitors were replaced with protease inhibitor cocktail tablets (Boehringer Mannheim). For immunoblotting, whole cell extracts were boiled in SDS-PAGE loading buffer, separated on 6% polyacrylamide gels and the proteins transferred to nitrocellulose using a wet-blotting apparatus. The Ku primary antibodies utilised were Ku80-4 and N3H10, raised against baculovirus-expressed Ku80 and Ku70 proteins, respectively (Serotec). The anti-XRCC4 antibody, SJ4A, was raised against full-length XRCC4 protein, as described previously [S4] . The antibody against DNA ligase IV was raised against a peptide comprising the carboxy-terminal residues 550 to 844 of DNA ligase IV inserted in-frame downstream of the hexahistidine (His 6 ) tag of pQE-30 (Qiagen). Filters were developed using an enhanced chemiluminescence (ECL) kit (Amersham).
Adenylation and ligation assays
DNA ligase IV from whole cell extracts was immunopurified by coimmunoprecipitation with anti-XRCC4 antibodies using universal buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, 25 mM β-glycerolphosphate, 0.1 mM sodium orthovanadate and protease inhibitor cocktail tablets). Immunoprecipitates were bound to protein-A-Sepharose beads (Sigma), washed twice with universal protease buffer containing 1 M NaCl, treated with 5 mM pyrophosphate and fresh protease inhibitors for 15 min at RT in the samples indicated, and then washed once with adenylation buffer (60 mM Tris-HCl pH 8.0, 10 mM MgCl 2 , 5 mM DTT, 50 µg/ml purified bovine serum albumin (BSA)). Samples were then used in western blotting or in adenylation and ligation assays, as described previously [S5] . Briefly, the immunoprecipated protein was resuspended in adenylation buffer plus protease inhibitors, and adenylation carried out with 10 µCi [α-32 P]ATP (800 Ci/mmol), or various other concentrations of ATP, at room temperature for 15 min. Samples were boiled in SDS-PAGE loading buffer and run on 6% polyacrylamide gels, fixed for 10 min in 10% acetic acid and dried, before exposure. For ligation, 1 mM ATP was added to the resuspended proteins together with the substrate. The substrate used was a radiolabelled 33mer plus an unlabeled 17mer annealed to a complementary 50mer, creating a nicked, double-stranded oligonucleotide. Ligation produces a radiolabelled 50mer. The sequence of the primers used are: 50mer, 5′GGGTGGATTCGTCCGCTGGAACCTTCCTTCCCTCCC-CTCGTCTAGATCCC; 17mer, 5′AGCGGACGAATCCACCC; 33mer, 5′GGGATCTAGACGAGGGGAGGGAAGGAAGGTTCC. Ligation was carried out at room temperature for 30 min. The samples were heated at 80°C in formamide-gel loading buffer for 3 min and run on a 12% denaturing polyacrylamide gel.
Synthesis and sequencing of cDNA
Total RNA was extracted from 3 × 10 6 cells using a purification kit involving Trizol Reagent (Life Technologies). A First Strand cDNA synthesis kit (Amersham Pharmacia Biotech) was used to synthesise cDNA. DNA ligase IV cDNA was amplified by RT-PCR and directly sequenced using the Thermo Sequenase 33 P-Radiolabeled Terminator Cycle Sequencing Kit (Amersham Life Science). XRCC4 cDNA was amplified by RT-PCR, the products cloned into pGEM-T (Promega) and analysed by automated DNA sequencing. Both strands of three clones were sequenced for XRCC4 from control and 180BR cells.
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Figure S1
Analysis of 180BR and 1BR cells for the expression of proteins involved in NHEJ. 
Expression of recombinant DNA ligase IV
For the in vitro transcription/translation system, amino-terminally Histagged DNA ligase IV cDNA was subcloned in-frame into the mammalian expression vector pcDNA3 (Invitrogen). The R278H mutation was introduced by site-directed mutagenesis using the QuickChange Tm Site-directed Mutagenesis Kit (Stratagene). The presence of the mutation was verified by DNA sequencing and restriction digestion. The wild-type and mutant constructs (2 µg of each) were expressed in 50 µl transcription/translation system buffer following the manufacturer's instructions (Promega TNT T7 Quick Coupled Transcription/Translation System). DNA ligase IV was affinity purified using an anti-His antibody (Clontech). The affinity-purified protein from three transcription/translation reactions was utilised for a combined experiment involving western blotting and an adenylation assay.
For the bacterial expression system, DNA ligase IV cDNA was cloned in-frame downstream of the His tag and S tag of pET30 (Novagen). The R278H mutation was introduced by swapping an NheI/DraIII restriction fragment of DNA ligase IV with the same fragment amplified from 180BR cells by RT-PCR. The presence of the mutation was confirmed by sequence analysis. The amino-terminal 213 residues of XRCC4 were cloned in-frame downstream of the His 6 tag of pET15b (Novagen). DNA ligase IV and XRCC4 were co-expressed in bacterial cells and purified using the His and S tags.
Yeast mutagenesis, strains and assays
Mutation of residues Lys282 and Arg287 to alanine, and Arg287 to histidine were performed using the Stratagene QuikChange Kit using as template either the full-length LIG4 gene cloned in pRS416 or the LIG4 ORF (with an amino-terminal His 6 and HA 2 tag) under the control of the GAL1-10 promoter cloned into pRS304. The non-mutated or mutated plasmids were transformed into W303a (pRS304-derived plasmids) or lig4 mutant (pRS416-derived plasmids) strains, respectively. The LIF1 open-reading frame was cloned (with an amino-terminal His 8 and FLAG tag) under the control of the GAL1-10 promoter in pRS306 and transformed into strains expressing either tagged wildtype or mutated LIG4p. Plasmid repair assays were performed as described previously using the plasmid pRS415 digested with XbaI [S6] . Immunoprecipitations were performed using whole cell extracts with either anti-HA antibodies (3F10; Boehringer Mannheim) or anti-FLAG antibodies (Sigma) in buffer containing 20 mM HEPES pH 7.5, 2 mM MgCl 2 , 2 mM EDTA, 20% glycerol, 0.5% NP40 and 1 M NaCl.
Immunoprecipitations were performed in strains expressing both tagged Lig4p and Lif1p.
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